Stanley Lapidus Joins Lucid Diagnostics as its Board Vice Chairman

PAVmed Inc., a highly differentiated, multi-product, commercial-stage medical technology company, announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former chairman and CEO of Exact Sciences, has joined its majority-owned subsidiary Lucid Diagnostics Inc. as vice chairman of Lucid’s Board of Directors.
 
“I am honored to welcome Stan Lapidus to Lucid’s Board of Directors,” said Lishan Aklog, M.D., PAVmed’s chairman and CEO and Lucid’s executive chairman. “Stan has long been a leading figure in the medical diagnostics industry and is one of its most accomplished innovators in the early detection of cancer—innovations which have prevented countless deaths from cervical and colon cancer. Over the past year, Stan has made invaluable contributions as Lucid’s lead strategic advisor, including helping us craft several key strategic initiatives currently underway. I look forward to working with him even more closely in his new role as Vice Chairman, as Lucid seeks to execute on its long-term growth strategy.”
 
Lapidus is a medical diagnostics pioneer who brings more than three decades of experience founding, leading, and advising breakthrough diagnostic companies, including founding and leading two of the most successful cancer early detection startup companies in history. He founded and served as president of Cytyc Inc., whose ThinPrep Pap test technology, which he invented, revolutionized early cervical cancer detection. Cytyc was acquired by Hologic Inc. in 2007. He also founded and served as president and CEO, and later as chairman, of Exact Sciences, whose Cologuard stool DNA test has revolutionized early detection of colorectal cancer.
 
Lapidus also serves as chairman of the boards of directors of Binx Health, a provider of point-of-care diagnostics tests; Mirvie, a maternal-fetal health diagnostic company; Mercy Bioanalytics, which is developing early cancer detection tests based on exosomes; and Droplet Biosciences, which is developing technology for detecting early recurrence of cancer. He also serves as a member of the boards of directors of Glympse Bio, which uses bioengineered sensors to track disease activity, and PathAI, an AI-based pathology company. Lapidus also serves as an Executive-in-Residence at the University of Colorado Anschutz Medical Campus, and as a co-founding Pillar of Pillar VC. He previously served as co-founder, president and CEO of SynapDx, a diagnostic company focused on laboratory tests for autism, and Helicos BioSciences Corp., a DNA sequencing company. He holds 37 U.S. patents.

Lapidus earned his bachelor of science degree in electrical engineering from the Cooper Union in New York City. He has served as an instructor at the Massachusetts Institute of Technology and was elected as a Fellow of the American Institute of Medical and Biological Engineering.

“My primary professional quest, over more than three decades, has been to save lives through the early detection of precancer and cancer. I am joining the Lucid team because they are on that very same quest—to prevent deaths from esophageal cancer as we have done for cervical and colon cancer,” said Lapidus. “EsoGuard, which was co-developed by a long-time colleague, collaborator and renowned cancer geneticist, Dr. Sandy Markowitz, has the opportunity to serve as a widespread screening tool to detect esophageal precancer in at-risk GERD patients. If you detect the precancer, you can remove or kill it and prevent its progression to cancer. By preventing cancer, you can save lives. This is the Lucid formula.”
 
PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer—the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure Esophageal Ablation Device with Caldus Technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Its minimally invasive Interventions division markets its CarpX Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy (PortIO Implantable Intraosseous Vascular Access Device and NextFlo Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support).